• Publications
  • Influence
Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association
Background—Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than for any other medicalExpand
  • 1,434
  • 64
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We reportExpand
  • 2,373
  • 59
  • PDF
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
CONTEXT Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure. OBJECTIVE To investigate the effects ofExpand
  • 1,336
  • 23
  • PDF
Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.
Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those withExpand
  • 427
  • 23
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.
Heart failure (HF) is a syndrome characterized by high mortality, frequent hospitalization, reduced quality of life, and a complex therapeutic regimen. Knowledge about HF is accumulating so rapidlyExpand
  • 675
  • 17
  • PDF
Acute Heart Failure Syndromes: Current State and Framework for Future Research
Acute heart failure syndromes (AHFS) poses unique diagnostic and management challenges. This syndrome has recently received attention from researchers, clinicians, regulatory agencies, and theExpand
  • 674
  • 16
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
CONTEXT Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promiseExpand
  • 739
  • 15
  • PDF
Heart failure: evaluation and care of patients with left ventricular systolic dysfunction.
  • 492
  • 14
Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)
Background—Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alone. Methods andExpand
  • 551
  • 14
Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.
OBJECTIVES We sought to evaluate the relationship between the level of kidney function, level of hematocrit and their interaction on all-cause mortality in patients with left ventricular (LV)Expand
  • 678
  • 13
  • PDF